ES2151489T3 - Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes. - Google Patents

Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes.

Info

Publication number
ES2151489T3
ES2151489T3 ES92911249T ES92911249T ES2151489T3 ES 2151489 T3 ES2151489 T3 ES 2151489T3 ES 92911249 T ES92911249 T ES 92911249T ES 92911249 T ES92911249 T ES 92911249T ES 2151489 T3 ES2151489 T3 ES 2151489T3
Authority
ES
Spain
Prior art keywords
herpes
treatment
composition
procedure
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911249T
Other languages
English (en)
Inventor
Ellis L Kline
Walter W Mcalhaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Rx Inc
Original Assignee
Molecular Rx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Rx Inc filed Critical Molecular Rx Inc
Application granted granted Critical
Publication of ES2151489T3 publication Critical patent/ES2151489T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE UN METODO Y COMPOSICION PARA TRATAMIENTO DE DOLENCIAS RELACIONADAS CON HERPES. LA INVENCION COMPRENDE LA ADMINISTRACION DE UN BAJO NIVEL DE PROTEINA NEURAMINIDASA O UN DERIVADO DE LA MISMA. EL METODO ES PARTICULARMENTE EFECTIVO EN EL TRATAMIENTO DE DOLENCIAS RELACIONADAS CON HERPES, TAL COMO ULCERAS FRIAS, LESIONES DE HERPES EN GENERAL Y SINDROME DE FATIGA CRONICA.
ES92911249T 1991-04-09 1992-04-06 Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes. Expired - Lifetime ES2151489T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68207191A 1991-04-09 1991-04-09
US86054692A 1992-04-03 1992-04-03

Publications (1)

Publication Number Publication Date
ES2151489T3 true ES2151489T3 (es) 2001-01-01

Family

ID=27102809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911249T Expired - Lifetime ES2151489T3 (es) 1991-04-09 1992-04-06 Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes.

Country Status (15)

Country Link
US (2) US5558863A (es)
EP (1) EP0579765B1 (es)
JP (1) JP3266254B2 (es)
AT (1) ATE196424T1 (es)
AU (1) AU662152B2 (es)
BR (1) BR9205877A (es)
CA (1) CA2108135C (es)
DE (1) DE69231465T2 (es)
DK (1) DK0579765T3 (es)
ES (1) ES2151489T3 (es)
GR (1) GR3035004T3 (es)
IE (1) IE921141A1 (es)
IL (1) IL101540A (es)
NO (1) NO313489B1 (es)
WO (1) WO1992018158A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272211B1 (en) * 2000-04-07 2007-06-06 Signal Coordinating Therapy, Inc. Methods and compositions for treating neoplasms
JP5414366B2 (ja) * 2009-05-29 2014-02-12 独立行政法人科学技術振興機構 疼痛治療剤
EP2900259B1 (en) * 2012-09-28 2020-04-15 Kline, Ellis Glycosidase regimen for treatment of infectious disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI790483A7 (fi) * 1978-02-16 1979-08-17 Science Union & Cie Foerfarande foer framstaellning av ett enzym av bakteriellt ursprung och farmaceutiska kompositioner innehaollande detsamma
JPS575916A (en) * 1980-06-13 1982-01-12 Teijin Ltd Polyester fiber with soft touch and production of knitted and woven fabrics therefrom

Also Published As

Publication number Publication date
AU1926492A (en) 1992-11-17
DK0579765T3 (da) 2000-10-09
IL101540A0 (en) 1992-12-30
DE69231465D1 (de) 2000-10-26
CA2108135C (en) 2008-03-11
DE69231465T2 (de) 2001-04-19
EP0579765A1 (en) 1994-01-26
EP0579765A4 (en) 1994-08-24
JPH06506698A (ja) 1994-07-28
CA2108135A1 (en) 1992-10-10
NO313489B1 (no) 2002-10-14
BR9205877A (pt) 1994-09-27
AU662152B2 (en) 1995-08-24
IL101540A (en) 1996-10-31
GR3035004T3 (en) 2001-03-30
IE921141A1 (en) 1992-10-21
JP3266254B2 (ja) 2002-03-18
US5558863A (en) 1996-09-24
NO933628D0 (no) 1993-10-08
ATE196424T1 (de) 2000-10-15
NO933628L (no) 1993-12-08
WO1992018158A1 (en) 1992-10-29
EP0579765B1 (en) 2000-09-20
US5736133A (en) 1998-04-07

Similar Documents

Publication Publication Date Title
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
DK0921812T3 (da) Insulinpræparater, som indeholder NaCi
NO990522L (no) Anvendelse av <beta>-ark mimetika som protease- og kinaseinhibatorer av transkripsjonsfaktorer
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2087160T3 (es) Composiciones y procedimiento para el tratamiento de trastornos dolorosos, inflamatorios o alergicos.
ES2192190T3 (es) Fragmentos proteicos tensioactivos pulmonares.
ITRM960364A0 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ES2192764T3 (es) Mimeticos de lamina beta y metodos relacionados con el uso de los mismos.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
ES2135254T3 (es) Procedimiento para la degradacion de quinolonas y naftiridonas.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
SE8403659L (sv) Synergistiska farmaceutiska kompositioner
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
CY2246B1 (en) Pharmaceutical compositions comprising calcitonin
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579765

Country of ref document: ES